← Back to Search

Monoclonal Antibodies

Radiation + Immunotherapy for Bile Duct Cancer

Phase 1
Waitlist Available
Led By Eugene J Koay
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky > 70)
Patients must have received at least one standard first-line chemotherapy regimen or have refused chemotherapy
Must not have
Major bleeding in the last 4 weeks
Receipt of any anticancer medication in the 21 days prior to receiving the first dose of study medication or any unresolved toxicity (> grade 1) from previous anticancer therapy, except for stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity. Prior treatment with nitrosoureas (e.g., carmustine or lomustine) require a 6-week washout prior to the first dose of study treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years post-treatment
Awards & highlights

Summary

This trial is to find the best dose of radiation and a new immunotherapy drug for bile duct cancer that has spread.

Who is the study for?
This trial is for adults with advanced bile duct cancer who have tried at least one chemotherapy or refused it. They must have two measurable tumors, be in good physical condition, and agree to use birth control. People can't join if they have autoimmune diseases, recent infections requiring antibiotics, major surgery within 4 weeks, received certain treatments recently, untreated brain metastases, are pregnant or breastfeeding.
What is being tested?
The trial tests a combination of hypofractionated radiation therapy (higher doses over a short period) and bintrafusp alfa (an immunotherapy drug). It aims to find the best dose and see how well this combo works against advanced intrahepatic cholangiocarcinoma by helping the immune system attack cancer.
What are the potential side effects?
Possible side effects include typical reactions from radiation like skin irritation and fatigue as well as immune-related effects from bintrafusp alfa such as flu-like symptoms, potential organ inflammation due to an overactive immune response, and infusion reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or have minor restrictions in physical activity.
Select...
I have undergone or refused initial chemotherapy.
Select...
I am 18 years old or older.
Select...
My kidney function, measured by creatinine levels or clearance, is normal.
Select...
My liver function tests are within the required range.
Select...
I have bile duct cancer with at least two tumors that can be measured.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had major bleeding in the last 4 weeks.
Select...
I haven't taken cancer drugs in the last 21 days and don't have major side effects from past treatments.
Select...
I have an autoimmune disease or am receiving treatment for one.
Select...
I have previously received treatments that boost the immune system to fight cancer.
Select...
I haven't had cancer treatment or experimental therapy in the last 2 weeks.
Select...
I do not have uncontrolled heart problems or a recent heart attack.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years post-treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events (AEs)
Secondary study objectives
Local progression free survival (LPFS)
Objective response rate
Overall survival (OS)
+1 more
Other study objectives
Biomarker analysis

Side effects data

From 2023 Phase 3 trial • 107 Patients • NCT03324802
80%
Dermatitis radiation
54%
Skin hyperpigmentation
48%
Pain
35%
Lymphedema
22%
Superficial soft tissue fibrosis
7%
Skin hypopigmentation
6%
Edema limbs
2%
Device related infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm 1 (Radiation Therapy, 15 Fractions)
Arm 2 (Hypofractionated Radiation Therapy, 5 Fractions)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (hypofractionated radiation, bintrafusp alfa)Experimental Treatment3 Interventions
Patients undergo hypofractionated radiation therapy QD on weekdays (Monday-Friday) for 15 fractions in the absence of disease progression or unacceptable toxicity. Beginning 1 week after completion of radiation therapy, patients receive bintrafusp alfa IV over 1 hour on day 1. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hypofractionated Radiation Therapy
2016
Completed Phase 3
~130
Biopsy
2014
Completed Phase 4
~1090
Bintrafusp Alfa
2021
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,686 Total Patients Enrolled
Eugene J KoayPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
315 Total Patients Enrolled

Media Library

Bintrafusp Alfa (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04708067 — Phase 1
Intrahepatic Cholangiocarcinoma Research Study Groups: Treatment (hypofractionated radiation, bintrafusp alfa)
Intrahepatic Cholangiocarcinoma Clinical Trial 2023: Bintrafusp Alfa Highlights & Side Effects. Trial Name: NCT04708067 — Phase 1
Bintrafusp Alfa (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04708067 — Phase 1
~6 spots leftby Feb 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top